Arno Therapeutics enrolls first patient in a Phase I/II trial evaluating onapristone in men with advanced castration-resistant prostate cancer
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, has announced that it has enrolled the first patient in a Phase I/II trial...
For active monitoring of prostate cancer, non-invasive imaging can be used instead of repeated biopsy
Your body's cells have two major interconnected energy sources: the lipid metabolism and the glucose metabolism.
Radiotherapy plus six months of hormone therapy improves prostate cancer survival
The findings, which were presented at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna, are expected to change clinical practice.
Research suggests prostate cancer may be prevented by circumcision
Men circumcised after the age of 35 were 45% less at risk of later developing prostate cancer than uncircumcised men, as shown by researchers at the University of Montreal and the...
Six months hormonal treatment in addition to radiotherapy improves survival for men with localised prostate cancer
Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.
New method for prostate cancer detection can save millions of men painful examination
Technique developed at Eindhoven University of Technology shows tumors with much greater precisionEach year prostate tissue samples are taken from over a million men around the world - in most cases using 12 large biopsy needles - to check whether they have prostate cancer.
Identifying men at high risk of prostate cancer recurrence
A new genetic "signature" to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna heard.
Major added benefit of Radium-223 dichloride for certain prostate cancer patients
Patients survive longer and get bone symptoms later / no evaluable data in comparison with docetaxelRadium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases.
New test could accurately predict prostate cancer recurrence
Researchers have created a test that they say can predict whether a man is at high risk of prostate cancer recurrence.The research team, led by Prof. Robert Bristow of the Princess Margaret Cancer Centre and the University of Toronto, both in Canada, presented their findings at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna, Italy.
Medication does not help prevent erectile dysfunction following radiation therapy for prostate cancer
Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in JAMA. Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer treatment.